$50.71
0.50% day before yesterday
NYSE, Apr 11, 10:10 pm CET
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Bristol-Myers Squibb Stock price

$50.71
-10.80 17.56% 1M
-1.49 2.85% 6M
-5.85 10.34% YTD
+1.59 3.24% 1Y
-25.79 33.71% 3Y
-8.21 13.93% 5Y
-13.24 20.70% 10Y
NYSE, Closing price Fri, Apr 11 2025
+0.25 0.50%
ISIN
US1101221083
Symbol
BMY
Sector
Industry

Key metrics

Market capitalization $103.18b
Enterprise Value $143.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 10.30
EV/Sales (TTM) EV/Sales 2.97
P/S ratio (TTM) P/S ratio 2.14
P/B ratio (TTM) P/B ratio 6.30
Dividend yield 4.77%
Last dividend (FY24) $2.42
Revenue growth (TTM) Revenue growth 7.32%
Revenue (TTM) Revenue $48.30b
EBIT (operating result TTM) EBIT $8.94b
Free Cash Flow (TTM) Free Cash Flow $13.94b
Cash position $10.86b
EPS (TTM) EPS $-4.43
P/E forward 9.08
P/S forward 2.26
EV/Sales forward 3.14
Short interest 1.45%
Show more

Is Bristol-Myers Squibb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Bristol-Myers Squibb Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Bristol-Myers Squibb forecast:

5x Buy
20%
19x Hold
76%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Bristol-Myers Squibb forecast:

Buy
20%
Hold
76%
Sell
4%

Financial data from Bristol-Myers Squibb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
48,300 48,300
7% 7%
100%
- Direct Costs 20,868 20,868
6% 6%
43%
27,432 27,432
8% 8%
57%
- Selling and Administrative Expenses - -
- Research and Development Expense 10,130 10,130
10% 10%
21%
18,489 18,489
1% 1%
38%
- Depreciation and Amortization 9,551 9,551
3% 3%
20%
EBIT (Operating Income) EBIT 8,938 8,938
6% 6%
19%
Net Profit -8,948 -8,948
212% 212%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Bristol-Myers Squibb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bristol-Myers Squibb Stock News

Neutral
Business Wire
one day ago
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma.
Negative
CNBC
one day ago
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC.  The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Positive
Barrons
2 days ago
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
More Bristol-Myers Squibb News

Company Profile

Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Head office United States
CEO Christopher Boerner
Employees 34,100
Founded 1933
Website www.bms.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today